Immunosuppression withdrawal following liver transplantation: The older, the wiser... but maybe too late

Hepatology

Volumn 58, Issue 5, 2013, Pages 1529-1532

  Levitsky, Josh ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

ADAPTATION; ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DRUG WITHDRAWAL; FOLLOW UP; GENE EXPRESSION; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; METABOLIC DISORDER; PATIENT SELECTION; PRIORITY JOURNAL;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE;

EID: 84887020261     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26576     Document Type: Article

References (19)

1. Starzl TE. The "privileged" liver and hepatic tolerogenicity. Liver Transpl 2001;7:918-920.
2. Calne RY, Sells RA, Pena JR, Davis DR, Millard PR, Herbertson BM, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969;223:472-476.
3. Calne RY, White HJ, Yoffa DE, Binns RM, Maginn RR, Herbertson RM, et al. Prolonged survival of liver transplants in the pig. Br Med J 1967;4:645-648.
4. Levitsky J. Operational tolerance: past lessons and future prospects. Liver Transpl 2011;17:222-232.
5. Benítez C, Londoño M-C, Miquel R, Manzia T-M, Abraldes JG, Lozano J-J, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013; 58:1824-1835.
6. Orlando G, Manzia T, Baiocchi L, Sanchez-Fueyo A, Angelico M, Tisone G. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol 2008;20:43-47.
7. Shaked A, Feng S, Punch J, Reyes G, Levitsky J, Klintmalm G, et al. Gradual withdrawal of immune system suppressing drugs in patients receiving a liver transplant (AWISH). National Institute of Allergy and Infectious Diseases, Immune Tolerance Network, NCT00135694 (clinicaltrials.gov).
8. Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012;307:283-293.
9. Banff Working Group on Liver Allograft Pathology. Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl 2012;18:1154-1170.
10. Pons JA, Ramirez P, Revilla-Nuin B, Pascual D, Baroja-Mazo A, Robles R, et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transplant 2009;23:329-336.
11. Bohne F, Martinez-Llordella M, Lozano JJ, Miquel R, Benitez C, Londono MC, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest 2012;122:368-382.
12. Levitsky J, Mathew JM, Abecassis M, Tambur A, Leventhal J, Chandrasekaran D, et al. Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology 2013;57:239-248.
13. Mathew JM, Ciancio G, Garcia-Morales R, Rosen A, Wang E, Gomez C, et al. Evaluation of immune tolerance profiles in donor bone marrow infused kidney transplant patients using multiple ex vivo assays. Hum Immunol 2010;71:566-576.
14. Lozano JJ, Pallier A, Martinez-Llordella M, Danger R, López M, Giral M, et al. Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transpl 2011;11:1916-1926.
15. Leventhal J, Abecassis M, Miller J, Gallon L, Ravindra K, Tollerud DJ, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012;4:124ra128.
16. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008;358:353-361.
17. Leventhal J, Mathew J, Salomon DR, Kurian SM, Suthanthiran M, Tambur A, et al. Genomic biomarkers correlate with HLA identical renal transplant tolerance - an interim report. J Am Soc Nephrol 2013 [Epub ahead of print].
18. Baan CC, van der Mast BJ, Klepper M, Mol WM, Peeters AM, Korevaar SS, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005;80:110-117.
19. Levitsky J, Gallon L, Miller J, Tambur A, Leventhal JFC, Huang X, et al. The differential effects of tacrolimus and sirolimus in the Treg MLR. Am J Transplant 2010;10:483.